| Literature DB >> 18996009 |
E Hampton Sessions1, Yan Yin, Thomas D Bannister, Amiee Weiser, Evelyn Griffin, Jennifer Pocas, Michael D Cameron, Claudia Ruiz, Li Lin, Stephan C Schürer, Thomas Schröter, Philip LoGrasso, Yangbo Feng.
Abstract
Inhibitors of Rho kinase have been developed based on two distinct scaffolds, benzimidazoles, and benzoxazoles. SAR studies and efforts to optimize the initial lead compounds are described. Novel selective inhibitors of ROCK-II with excellent potency in both enzyme and cell-based assays were obtained. These inhibitors possess good microsomal stability, low cytochrome P-450 inhibitions and good oral bioavailability.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18996009 DOI： 10.1016/j.bmcl.2008.10.095
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823